An Evaluation of Reproductive and Developmental Toxicity of Sitaxentan (Thelin) in Rats

Birth Defects Research Part B - Developmental and Reproductive Toxicology

Volumn 95, Issue 5, 2012, Pages 327-336

  Cross, David M ^a   Horsley, Elizabeth ^a   Derzi, Mazin ^b   Owen, Keith ^a   Stavros, Fiona L ^c  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b PFIZER INC   (United States)

^c Jackrabbit Consulting LLC   (United States)

Author keywords

Development; Endothelin; Fertility; Fetus; Postnatal; Prenatal; Sitaxentan; Toxicity

Indexed keywords

SITAXSENTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR MALFORMATION; CONGENITAL MALFORMATION; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; DRUG MECHANISM; EMBRYO DEVELOPMENT; FACE MALFORMATION; FEMALE; FEMALE FERTILITY; HEAD MALFORMATION; LARGE BLOOD VESSEL MALFORMATION; MALE; MALE FERTILITY; MOUTH MALFORMATION; NONHUMAN; PRIORITY JOURNAL; RAT; REPRODUCTIVE TOXICITY; TERATOGENICITY;

ANIMALS; ANIMALS, NEWBORN; CROSSES, GENETIC; EMBRYONIC DEVELOPMENT; EVALUATION STUDIES AS TOPIC; FEMALE; FERTILITY; FETUS; ISOXAZOLES; MALE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCTION; THIOPHENES; TOXICITY TESTS; WEANING;

EID: 84867342891     PISSN: 15429733     EISSN: 15429741     Source Type: Journal    
DOI: 10.1002/bdrb.21021     Document Type: Article

References (45)

1. Barst RJ, Gibbs JS, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, Sitbon O, Tapson VF, Galie N. 2009. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 54(1 Suppl):S78-S84.
2. Casey ML, Byrd W, MacDonald PC. 1992. Massive amounts of immunoreactive endothelin in human seminal fluid. J Clin Endocrinol Metab 74(1):223-225.
3. Clouthier DE, Hosoda K, Richardson JA, Williams SC, Yanagisawa H, Kuwaki T, Kumada M, Hammer RE, Yanagisawa M. 1998. Cranial and cardiac neural crest defects in endothelin-A receptor-deficient mice. Development 125(5):813-824.
4. Conte D, Questino P, Fillo S, Nordio M, Isidori A, Romanelli F. 1993. Endothelin stimulates testosterone secretion by rat Leydig cells. J Endocrinol 136(2):R1-R4.
5. Cross D, Derzi M, Horsley E, Owen K, Stavros F. 2012. Evaluation of sitaxentan (Thelin®) toxicity in juvenile rats and regulatory interactions during the development of a European Medicines Agency Paediatric Investigation Plan. Regulatory Toxicology and Pharmacology 64:43-50.
6. Data on File. 2006. New York, NY: Pfizer Inc.
7. Davenport AP, Cameron IT, Smith SK, Brown MJ. 1991. Binding sites for iodinated endothelin-1, endothelin-2 and endothelin-3 demonstrated on human uterine glandular epithelial cells by quantitative high-resolution autoradiography. J Endocrinol 129(1):149-154.
8. Elliot CA, Stewart P, Webster VJ, Mills GH, Hutchinson SP, Howarth ES, Bu'lock FA, Lawson RA, Armstrong IJ, Kiely DG 2005. The use of iloprost in early pregnancy in patients with pulmonary arterial hypertension. Eur Respir J 26(1):168-173.
9. Ergun S, Harneit S, Paust HJ, Mukhopadhyay AK, Holstein AF. 1999. Endothelin and endothelin receptors A and B in the human testis. Anat Embryol (Berl) 199(3):207-214.
10. European Medicines Agency. 1994. ICH Topic S 5 (R2) Detection of toxicity to reproduction for medicinal products & toxicity to male fertility Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002809.pdf. Accessed January 30, 2012.
11. European Medicines Agency. 2007. Thelin scientific discussion: European Public Assessment Report. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000679/WC500037904.pdf. Accessed January 30, 2012.
12. Filippini A, Tripiciano A, Palombi F, Teti A, Paniccia R, Stefanini M, Ziparo E. 1993. Rat testicular myoid cells respond to endothelin: characterization of binding and signal transduction pathway. Endocrinology 133(4):1789-1796.
13. Fukuroda T, Fujikawa T, Ozaki S, Ishikawa K, Yano M, Nishikibe M. 1994. Clearance of circulating endothelin-1 by ETBreceptors in rats. Biochem Biophys Res Commun 199(3):1461-1465.
14. Galie N, Hoeper MM, Simon J, Gibbs R, Simonneau G. 2011. Liver toxicity of sitaxentan in pulmonary arterial hypertension. Eur Heart J 32(4):386-387.
15. Gariepy CE, Ohuchi T, Williams SC, Richardson JA, Yanagisawa M. 2000. Salt-sensitive hypertension in endothelin-B receptor-deficient rats. J Clin Invest 105(7):925-933.
16. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ. 1993. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328(24):1732-1739.
17. Hammami MM, Haq A, AlSedairy S. 1994. The level of endothelin-like immunoreactivity in seminal fluid correlates positively with semen volume and negatively with plasma gonadotrophin levels. Clin Endocrinol (Oxf) 40(3):361-366.
18. Harneit S, Ergun S, Paust HJ, Mukhopadhyay AK, Holstein AF. 1997a. Endothelin-1 and its receptors in the human epididymis. Adv Exp Med Biol 424:191-192.
19. Harneit S, Paust HJ, Mukhopadhyay AK, Ergun S. 1997b. Localization of endothelin-1 and endothelin-receptors A and B in human epididymis. Mol Hum Reprod 3(7):579-584.
20. Higton AM, Whale C, Musk M, Gabbay E. 2009. Pulmonary hypertension in pregnancy: two cases and review of the literature. Intern Med J 39(11):766-770.
21. Hosoda K, Hammer RE, Richardson JA, Baynash AG, Cheung JC, Giaid A, Yanagisawa M. 1994. Targeted and natural (piebald-lethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat color in mice. Cell 79(7):1267-1276.
22. Huang S, DeSantis ER. 2007. Treatment of pulmonary arterial hypertension in pregnancy. Am J Health Syst Pharm 64(18):1922-1926.
23. Humbert M, Sitbon O, Simonneau G. 2004. Treatment of pulmonary arterial hypertension. N Engl J Med 351(14):1425-1436.
24. Johnstrom P, Harris NG, Fryer TD, Barret O, Clark JC, Pickard JD, Davenport AP. 2002. (18)F-Endothelin-1, a positron emission tomography (PET) radioligand for the endothelin receptor system: radiosynthesis and in vivo imaging using microPET. Clin Sci (Lond) 103(Suppl 48):4S-8S.
25. Karam H, Valdenaire O, Belair MF, Prigent-Sassy C, Rakotosalama A, Clozel M, Itskovitz J, Bruneval P. 1999. The endothelin system in human and monkey ovaries: in situ gene expression of the different components. Cell Tissue Res 295(1):101-109.
26. Kurihara Y, Kurihara H, Suzuki H, Kodama T, Maemura K, Nagai R, Oda H, Kuwaki T, Cao WH, Kamada N, Jishage K, Ouchi Y, Azuma S, Toyoda Y, Ishikawa T, Kumada M, Yazaki Y. 1994. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 368(6473):703-710.
27. Letairis (ambrisentan). 2008. Full prescribing information. Foster City, CA: Gilead Sciences Inc.
28. Luscher TF, Barton M. 2000. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 102(19):2434-2440.
29. Lutz J, Gorenflo M, Habighorst M, Vogel M, Lange PE, Hocher B. 1999. Endothelin-1- and endothelin-receptors in lung biopsies of patients with pulmonary hypertension due to congenital heart disease. Clin Chem Lab Med 37(4):423-428.
30. Maggi M, Barni T, Orlando C, Fantoni G, Finetti G, Vannelli GB, Mancina R, Gloria L, Bonaccorsi L, Yanagisawa M, Forti G. 1995. Endothelin-1 and its receptors in human testis. J Androl 16(3):213-224.
31. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J. 2009. ACCF/AHA2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 53(17):1573-1619.
32. Meidan R, Levy N. 2007. The ovarian endothelin network: an evolving story. Trends Endocrinol Metab 18(10):379-385.
33. Molelekwa V, Akhter P, McKenna P, Bowen M, Walsh K. 2005. Eisenmenger's syndrome in a 27 week pregnancy-management with bosentan and sildenafil. Ir Med J 98(3):87-88.
34. Owen K, Derzi M, Horsley E, Cross D, Stavros F. 2012. An overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (Thelin®), a potent endothelin receptor antagonist (ETA) developed for pulmonary arterial hypertension. Regulatory Toxicology and Pharmacology 64:95-103.
35. Peri A, Fantoni G, Granchi S, Vannelli GB, Barni T, Amerini S, Pupilli C, Barbagli G, Forti G, Serio M, Maggi M. 1997. Gene expression of endothelin-1, endothelin-converting enzyme-1, and endothelin receptors in human epididymis. J Clin Endocrinol Metab 82(11):3797-3806.
36. Plumpton C, Ferro CJ, Haynes WG, Webb DJ, Davenport AP. 1996. The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044. Br J Pharmacol 119(2):311-314.
37. Rosano L, Di Castro V, Spinella F, Tortora G, Nicotra MR, Natali PG, Bagnato A. 2007. Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity. Cancer Res 67(13):6351-6359.
38. Rubens C, Ewert R, Halank M, Wensel R, Orzechowski HD, Schultheiss HP, Hoeffken G. 2001. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 120(5):1562-1569.
39. Sharma OP, Flores JA, Leong DA, Veldhuis JD. 1994. Mechanisms by which endothelin-1 stimulates increased cytosolic free calcium ion concentrations in single rat Sertoli cells. Endocrinology 135(1):127-134.
40. Thelin (sitaxentan) 100 mg. 2009. Summary of Product Characteristics. Sandwich, UK: Pfizer Ltd.
41. Tracleer (bosentan). 2009. Full Prescribing Information. South San Francisco, CA: Actelion Pharmaceuticals US, Inc.
42. Treinen KA, Louden C, Dennis MJ, Wier PJ. 1999. Developmental toxicity and toxicokinetics of two endothelin receptor antagonists in rats and rabbits. Teratology 59(1):51-59.
43. Weiss BM, Zemp L, Seifert B, Hess OM. 1998. Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. J Am Coll Cardiol 31(7):1650-1657.
44. Wu C, Chan MF, Stavros F, Raju B, Okun I, Mong S, Keller KM, Brock T, Kogan TP, Dixon RA. 1997. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist. J Med Chem 40(11):1690-1697.
45. Yoshibayashi M, Nishioka K, Nakao K, Saito Y, Matsumura M, Ueda T, Temma S, Shirakami G, Imura H, Mikawa H. 1991. Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation. Circulation 84(6):2280-2285.